Activation of PKCα is strongly implicated in the progression of AD, mutations in PKCα significantly increase the risk of AD, and a slight increase in PKCα activity sufficient to lead to the development of an AD phenotype in mice.[66] Thus, our data indicate that PEDF may act as a novel endogenous inhibitor of PKCα activity. The gene discussed is PRKCA; the disease is Alzheimer disease.